Natesto
Orchitis, Puberty, Delayed, Gonadotrophin releasing hormone deficiency + 9 more
Treatment
17 FDA approvals
3 Active Studies for Natesto
Treatment for
Orchitis
What is Natesto
Testosterone
The Generic name of this drug
Treatment Summary
Testosterone is a male sex hormone used to treat conditions caused by low or absent testosterone levels in the body. Testosterone works by activating certain genes in the body which are responsible for the development of male reproductive organs and secondary sex characteristics. Testosterone was first isolated and synthesized in 1935.
Androderm
is the brand name
Natesto Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Androderm
Testosterone
1995
90
Approved as Treatment by the FDA
Testosterone, commonly known as Androderm, is approved by the FDA for 17 uses including Spermatic Cord Torsion and Puberty, Delayed .
Spermatic Cord Torsion
Helps manage Torsion of testis
Puberty, Delayed
Used to treat Puberty, Delayed in combination with Testosterone enanthate
Hypogonadism
Helps manage Hypergonadotropic Hypogonadism
Breast
Used to treat inoperable, metastatic Breast cancer in combination with Testosterone enanthate
Torsion of testis
Helps manage Torsion of testis
Hypothalamo-pituitary disorder
Helps manage Hypothalamo-pituitary disorder
Delayed Puberty
Used to treat Puberty, Delayed in combination with Testosterone enanthate
Orchitis
Helps manage Orchitis
Orchitis
Helps manage Orchitis
Hypergonadotropic Hypogonadism
Helps manage Hypergonadotropic Hypogonadism
Hypogonadotropic hypogonadism
Gonadotrophin releasing hormone deficiency
Helps manage Gonadotrophin releasing hormone deficiency
1 to 5 years post-menopausal
Used to treat 1 to 5 years post-menopausal in combination with Testosterone enanthate
Anorchia
Helps manage vanishing testis syndrome
Orchidectomy
Helps manage Orchidectomy
inoperable, metastatic Breast cancer
Used to treat inoperable, metastatic Breast cancer in combination with Testosterone enanthate
Hypogonadism
Helps manage Idiopathic Hypogonadotropic Hypogonadism
Effectiveness
How Natesto Affects Patients
Testosterone helps to create the physical traits and organs associated with being male. How long it works can vary from person to person, but it typically lasts 10-100 minutes. This drug is considered safe, as normal testosterone levels in adult men range from 300-1000ng/dL. It's important to be aware that this drug can be transferred to children through skin contact, so patients should be warned of this risk.
How Natesto works in the body
The androgen receptor is a protein found in cells throughout the body. It binds to male hormones like testosterone, allowing them to enter the cell. The androgen receptor can then move into the nucleus, which activates the genes needed for male development. This includes the growth of organs like the prostate, penis, and scrotum, as well as secondary sexual characteristics like facial and body hair.
When to interrupt dosage
The recommended quantity of Natesto is contingent upon the diagnosed condition, such as Gonadotrophin releasing hormone deficiency, Orchidectomy and Orchitis. The amount of dosage shifts in line with the method of administration specified in the table below.
Condition
Dosage
Administration
Breast
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular
Orchitis
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular
Puberty, Delayed
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular
Gonadotrophin releasing hormone deficiency
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular
1 to 5 years post-menopausal
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular
Hypothalamo-pituitary disorder
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular
Orchidectomy
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular
Spermatic Cord Torsion
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular
Hypogonadism
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular
Hypogonadotropic hypogonadism
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular
Anorchia
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular
Hypogonadism
, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg
, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular
Warnings
Natesto Contraindications
Condition
Risk Level
Notes
suspected pregnancy
Do Not Combine
Breast Cancer
Do Not Combine
There are 20 known major drug interactions with Natesto.
Common Natesto Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be increased when combined with Testosterone.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Testosterone.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Testosterone.
Aminophylline
Major
The metabolism of Aminophylline can be increased when combined with Testosterone.
Astemizole
Major
The metabolism of Astemizole can be increased when combined with Testosterone.
Natesto Toxicity & Overdose Risk
There is not much information on overdosing on topical testosterone products. However, if someone takes an injectable form of this drug, they may suffer a stroke. To treat an overdose, stop taking the testosterone, wash off any topical product with soap and water, and get medical help for any symptoms.
Natesto Novel Uses: Which Conditions Have a Clinical Trial Featuring Natesto?
Presently, 10 active clinical trials are analyzing the potential of Natesto to reduce the symptoms of Orchitis, Testicular Torsion and Hypothalamo-pituitary Dysfunction.
Condition
Clinical Trials
Trial Phases
Hypothalamo-pituitary disorder
0 Actively Recruiting
1 to 5 years post-menopausal
0 Actively Recruiting
Hypogonadism
0 Actively Recruiting
Orchitis
0 Actively Recruiting
Spermatic Cord Torsion
0 Actively Recruiting
Orchidectomy
0 Actively Recruiting
Breast
0 Actively Recruiting
Hypogonadotropic hypogonadism
0 Actively Recruiting
Puberty, Delayed
0 Actively Recruiting
Gonadotrophin releasing hormone deficiency
0 Actively Recruiting
Anorchia
0 Actively Recruiting
Hypogonadism
3 Actively Recruiting
Phase 2
Natesto Reviews: What are patients saying about Natesto?
5
Patient Review
5/1/2018
Natesto for Deficiency of Luteinizing Hormone-Releasing Hormone
5
Patient Review
3/20/2018
Natesto for Primary Testicular Failure due to Inflammation of Testis
5
Patient Review
10/21/2022
Natesto for Deficiency of a Substance that Promotes Masculinization
5
Patient Review
10/18/2015
Natesto for Deficient Activity of the Testis
5
Patient Review
11/10/2017
Natesto for Pituitary Hormone Deficiency
4.7
Patient Review
5/30/2019
Natesto for Deficient Activity of the Testis
4.3
Patient Review
8/6/2020
Natesto for Deficient Activity of the Testis
4.3
Patient Review
3/14/2019
Natesto for Deficiency of a Substance that Promotes Masculinization
4.3
Patient Review
12/21/2015
Natesto for Deficient Activity of the Testis
4
Patient Review
12/13/2018
Natesto for Deficient Activity of the Testis
3.7
Patient Review
6/10/2020
Natesto for Deficient Activity of the Testis
2.3
Patient Review
2/1/2022
Natesto for Deficient Activity of Testes or Ovaries due to Chemotherapy
Patient Q&A Section about natesto
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is Natesto used for?
"Natesto is a prescription medication that contains testosterone and is designed to treat adult males who have low or no testosterone due to certain medical conditions. Your healthcare provider will test your testosterone levels in your blood before you start and while you are using Natesto."
Answered by AI
Is Natesto FDA approved?
"The US Food and Drug Administration approved Natesto Nasal Gel in May for adult males who have a deficiency or absence of the hormone testosterone due to conditions like primary hypogonadism or hypogonadotropic hypogonadism."
Answered by AI
How long does it take for Natesto to work?
"Testosterone levels reach their appropriate level within 40 minutes of using Natesto. You may start seeing your symptoms improve soon after taking the medication. Use Natesto at the same time every day to keep your testosterone levels normal."
Answered by AI
Is Natesto discontinued?
"Natesto has not been permanently discontinued in the United States."
Answered by AI